- Home
- NUS vs CADL Comparison
NUS vs CADL Comparison
Compare NUS & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- CADL
- Stock Information
- Founded
- NUS 1984
- CADL 1999
- Country
- NUS United States
- CADL United States
- Employees
- NUS N/A
- CADL N/A
- Industry
- NUS Other Pharmaceuticals
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- NUS Health Care
- CADL Health Care
- Exchange
- NUS Nasdaq
- CADL Nasdaq
- Market Cap
- NUS 321.6M
- CADL 306.4M
- IPO Year
- NUS 1996
- CADL 2021
- Fundamental
- Price
- NUS $7.70
- CADL $8.06
- Analyst Decision
- NUS Hold
- CADL Strong Buy
- Analyst Count
- NUS 2
- CADL 4
- Target Price
- NUS $6.88
- CADL $21.00
- AVG Volume (30 Days)
- NUS 671.4K
- CADL 1.2M
- Earning Date
- NUS 05-07-2025
- CADL 03-13-2025
- Dividend Yield
- NUS 2.94%
- CADL N/A
- EPS Growth
- NUS N/A
- CADL N/A
- EPS
- NUS N/A
- CADL N/A
- Revenue
- NUS $1,732,084,000.00
- CADL N/A
- Revenue This Year
- NUS N/A
- CADL N/A
- Revenue Next Year
- NUS N/A
- CADL N/A
- P/E Ratio
- NUS N/A
- CADL N/A
- Revenue Growth
- NUS N/A
- CADL N/A
- 52 Week Low
- NUS $5.95
- CADL $1.40
- 52 Week High
- NUS $14.04
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- NUS 48.92
- CADL 45.77
- Support Level
- NUS $7.98
- CADL $8.33
- Resistance Level
- NUS $8.35
- CADL $9.08
- Average True Range (ATR)
- NUS 0.33
- CADL 0.59
- MACD
- NUS -0.05
- CADL -0.04
- Stochastic Oscillator
- NUS 32.67
- CADL 42.70
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.